Study ID | Sample size | Diagnostic criteria | Test design | Course (weeks) | Follow-up (months) | Major outcomes | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Randomizer | Blindness | Efficacy by HAMD | Clinical efficacy | Side effects | Relapse | Onset time | |||||
Wang et al. [9] | 120 | CCMD-3 | Xiaoyao pill and duloxetine | Duloxetine | N/A | N/A | 8 | N/A | ↑ | ↑ (CGI) | NS (TESS) | N/A | N/A |
Wang et al. [10] | 68 | CCMD-3 | Xiaoyao pill and doxepin | Fluoxetine | N/A | N/A | 6 | N/A | NS | NS | NS (TESS) | N/A | ↑ |
Nan et al. [11] | 61 | CCMD-2-R | Xiaoyao pill and imipramine | Imipramine | N/A | N/A | 8 | 6 | NS | ↑ (cure rate) | ↓ | ↓ | N/A |
Li et al. [12] | 60 | CCMD-3 | Xiaoyao pill and imipramine | Imipramine | N/A | N/A | 8 | N/A | NS | NS | ↓ | N/A | ↑ |
Du et al. [13] | 150 | CCMD-3 | Xiaoyao pill and fluoxetine | Amitriptyline | N/A | N/A | 6 | N/A | NS | NS | ↓ (TESS) | N/A | ↑ |
Ma [14] | 30 | CCMD-3 | Xiaoyao pill and citalopram | Citalopram | Random number table | N/A | 8 | 12 | NS | NS | ↓ (TESS) | ↓ | N/A |
Chen [15] | 61 | CCMD-2-R | Xiaoyao pill and amitriptyline | Amitriptyline | N/A | N/A | 6 | 6 | ↑ | ↑ | ↓ (TESS) | ↓ | N/A |
Zhai et al. [16] | 24 | CCMD-2-R | Xiaoyao pill and doxepin | Doxepin | N/A | N/A | 8 | N/A | NS | NS | ↓ (TESS) | N/A | N/A |
Zhang et al. [17] | 50 | CCMD-3 | Xiaoyao pill and fluoxetine | Fluoxetine | N/A | N/A | 6 | N/A | NS | NS | ↓ (TESS) | N/A | ↑ |
Zhang et al. [18] | 50 | CCMD-2-R | Xiaoyao pill and fluoxetine | fluoxetine | N/A | N/A | 3 | N/A | N/A | ↑ (Zung value) | ↓ (TESS) | N/A | N/A |
Xia et al. [19] | 60 | CCMD-3 | Xiaoyao pill and citalopram | Citalopram | N/A | N/A | 8 | N/A | ↑ | ↑ | ↓ (TESS) | N/A | N/A |
Xiang [20] | 76 | CCMD-3 | Xiaoyao pill and paroxetine | Paroxetine | N/A | N/A | 12 | 12 | N/A | ↑ (SDS) | N/A | ↓ | N/A |